Published in J Clin Pharmacol on October 01, 2009
Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res (2010) 1.89
Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res (2010) 1.82
Resveratrol: French paradox revisited. Front Pharmacol (2012) 1.40
The journey of resveratrol from yeast to human. Aging (Albany NY) (2012) 1.22
Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des (2013) 1.22
Resveratrol suppresses body mass gain in a seasonal non-human primate model of obesity. BMC Physiol (2010) 1.16
Bioavailability challenges associated with development of anti-cancer phenolics. Mini Rev Med Chem (2010) 1.10
Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases--safety, pharmacokinetics, and pharmacodynamics. Cancer Prev Res (Phila) (2011) 1.06
Resveratrol--pills to replace a healthy diet? Br J Clin Pharmacol (2011) 1.02
O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. Cell Death Dis (2013) 0.98
The grape antioxidant resveratrol for skin disorders: promise, prospects, and challenges. Arch Biochem Biophys (2011) 0.88
An Organ System Approach to Explore the Antioxidative, Anti-Inflammatory, and Cytoprotective Actions of Resveratrol. Oxid Med Cell Longev (2015) 0.82
Analytical method development for synthesized conjugated metabolites of trans-resveratrol, and application to pharmacokinetic studies. J Pharm Biomed Anal (2011) 0.80
Resveratrol as a therapeutic agent for Alzheimer's disease. Biomed Res Int (2014) 0.79
The role of reactive oxygen species and subsequent DNA-damage response in the emergence of resistance towards resveratrol in colon cancer models. Cell Death Dis (2014) 0.79
Resveratrol and Ophthalmic Diseases. Nutrients (2016) 0.78
Physicochemical properties of dietary phytochemicals can predict their passive absorption in the human small intestine. Sci Rep (2017) 0.75
Cancer chemoprevention through dietary flavonoids: what's limiting? Chin J Cancer (2017) 0.75
Effects of Resveratrol on Cognitive Performance, Mood and Cerebrovascular Function in Post-Menopausal Women; A 14-Week Randomised Placebo-Controlled Intervention Trial. Nutrients (2017) 0.75
Tissue Distribution of trans-Resveratrol and Its Metabolites after Oral Administration in Human Eyes. J Ophthalmol (2017) 0.75
Development of a lozenge for oral transmucosal delivery of trans-resveratrol in humans: proof of concept. PLoS One (2014) 0.75
Understanding physician antibiotic prescribing behaviour: a systematic review of qualitative studies. Int J Antimicrob Agents (2012) 1.87
Intranasal drug delivery: how, why and what for? J Pharm Pharm Sci (2009) 1.63
Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res (2009) 1.47
Why healthy subjects volunteer for phase I studies and how they perceive their participation? Eur J Clin Pharmacol (2007) 1.45
Coordinated waves of actomyosin flow and apical cell constriction immediately after wounding. J Cell Biol (2013) 1.14
Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics (2007) 1.09
Decrease of adenosine A1 receptor density and of adenosine neuromodulation in the hippocampus of kindled rats. Eur J Neurosci (2003) 1.06
Catechol-O-methyltransferase and its inhibitors in Parkinson's disease. CNS Drug Rev (2007) 1.03
Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Epilepsy Res (2012) 1.03
Use of off-label and unlicenced drugs in hospitalised paediatric patients: a systematic review. Eur J Clin Pharmacol (2014) 1.03
Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia (2007) 0.99
Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Saf (2012) 0.98
Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Epilepsia (2012) 0.98
Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events. Eur J Clin Pharmacol (2008) 0.98
Aging increases oxidative stress and renal expression of oxidant and antioxidant enzymes that are associated with an increased trend in systolic blood pressure. Oxid Med Cell Longev (2010) 0.97
Long-term efficacy and safety of eslicarbazepine acetate: results of a 1-year open-label extension study in partial-onset seizures in adults with epilepsy. Epilepsia (2010) 0.96
Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia (2012) 0.96
Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children and adolescents with epilepsy. J Clin Pharmacol (2008) 0.94
Renal amino acid transport systems and essential hypertension. FASEB J (2013) 0.94
Gialpha3 protein-coupled dopamine D3 receptor-mediated inhibition of renal NHE3 activity in SHR proximal tubular cells is a PLC-PKC-mediated event. Am J Physiol Renal Physiol (2004) 0.94
Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects. J Clin Pharmacol (2005) 0.93
Computation of the binding affinities of catechol-O-methyltransferase inhibitors: multisubstate relative free energy calculations. J Comput Chem (2012) 0.92
Long-term effect of convulsive behavior on the density of adenosine A1 and A 2A receptors in the rat cerebral cortex. Epilepsia (2005) 0.92
Dopamine D3 receptor-mediated inhibition of Na+/H+ exchanger activity in normotensive and spontaneously hypertensive rat proximal tubular epithelial cells. Br J Pharmacol (2004) 0.91
Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans. J Clin Pharmacol (2004) 0.91
Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker. Biopharm Drug Dispos (2007) 0.89
Surfactants as microbicides and contraceptive agents: a systematic in vitro study. PLoS One (2008) 0.88
H2O2 stimulation of the Cl-/HCO3- exchanger by angiotensin II and angiotensin II type 1 receptor distribution in membrane microdomains. Hypertension (2008) 0.87
Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem (2010) 0.87
Intestinal Na+-K+-ATPase activity and molecular events downstream of interferon-gamma receptor stimulation. Br J Pharmacol (2004) 0.86
JC virus in the pathogenesis of colorectal cancer, an etiological agent or another component in a multistep process? Virol J (2010) 0.86
Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility. J Med Chem (2014) 0.86
Age-related changes in renal expression of oxidant and antioxidant enzymes and oxidative stress markers in male SHR and WKY rats. Exp Gerontol (2011) 0.86
Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. Drugs R D (2010) 0.85
JNK signalling controls remodelling of the segment boundary through cell reprogramming during Drosophila morphogenesis. PLoS Biol (2010) 0.85
High-salt intake and the renal expression of amino acid transporters in spontaneously hypertensive rats. Am J Physiol Renal Physiol (2007) 0.85
Oxidative stress and the genomic regulation of aldosterone-stimulated NHE1 activity in SHR renal proximal tubular cells. Mol Cell Biochem (2007) 0.85
Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia (2014) 0.85
Dopamine acutely decreases type 3 Na(+)/H(+) exchanger activity in renal OK cells through the activation of protein kinases A and C signalling cascades. Eur J Pharmacol (2004) 0.84
Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. Clin Neuropharmacol (2008) 0.84
Single-dose tolerability, pharmacokinetics, and pharmacodynamics of etamicastat (BIA 5-453), a new dopamine β-hydroxylase inhibitor, in healthy subjects. J Clin Pharmacol (2012) 0.83
Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans. Drugs R D (2003) 0.83
Dosage form proportionality and food effect of the final tablet formulation of eslicarbazepine acetate: randomized, open-label, crossover, single-centre study in healthy volunteers. Drugs R D (2008) 0.83
Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. Clin Neuropharmacol (2004) 0.82
Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093). Drugs R D (2005) 0.82
Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem (2004) 0.82
Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol (2013) 0.82
New insights into the regulation of Na+,K+-ATPase by ouabain. Int Rev Cell Mol Biol (2012) 0.82
Upregulation of apical NHE3 in renal OK cells overexpressing the rodent alpha(1)-subunit of the Na(+) pump. Am J Physiol Regul Integr Comp Physiol (2005) 0.82
Pharmacokinetics and tolerability of etamicastat following single and repeated administration in elderly versus young healthy male subjects: an open-label, single-center, parallel-group study. Clin Ther (2011) 0.82
Signaling of short- and long-term regulation of intestinal epithelial type 1 Na+/H+ exchanger by interferon-gamma. Br J Pharmacol (2005) 0.82
Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clin Pharmacokinet (2013) 0.82
Activity and regulation of Na+-HCO3- cotransporter in immortalized spontaneously hypertensive rat and Wistar-Kyoto rat proximal tubular epithelial cells. Hypertension (2007) 0.82
Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. Eur J Clin Pharmacol (2003) 0.82
Pharmacokinetic and pharmacodynamic profiles of BIA 3-202, a novel catechol-O-methyltransferase (COMT) inhibitor, during multiple-dose administration to healthy subjects. J Clin Pharmacol (2003) 0.82
Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women. Epilepsy Res (2013) 0.81
EEG sources in a group of patients with major depressive disorders. Int J Psychophysiol (2008) 0.81
Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundam Clin Pharmacol (2009) 0.81
Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study. Clin Ther (2010) 0.81
CA-125 AUC as a predictor for epithelial ovarian cancer relapse. Cancer Biomark (2008) 0.81
Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects. Int J Clin Pharmacol Ther (2009) 0.81
Bioavailability and bioequivalence of two enteric-coated formulations of omeprazole in fasting and fed conditions. Clin Drug Investig (2005) 0.81
Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol (2014) 0.81
Interferon-gamma-induced STAT1-mediated membrane retention of NHE1 and associated proteins ezrin, radixin and moesin in HT-29 cells. Biochem Pharmacol (2005) 0.81
The L-3,4-dihydroxyphenylalanine transporter in human and rat epithelial intestinal cells is a type 2 hetero amino acid exchanger. Eur J Pharmacol (2002) 0.81
Evaluation of the permeability and P-glycoprotein efflux of carbamazepine and several derivatives across mouse small intestine by the Ussing chamber technique. Epilepsia (2012) 0.81
Eslicarbazepine acetate (BIA 2-093) : relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200mg and 800mg tablet formulations. Drugs R D (2005) 0.81